Compare SRPT & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRPT | JLS |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 94.1M |
| IPO Year | 2000 | 2009 |
| Metric | SRPT | JLS |
|---|---|---|
| Price | $20.61 | $16.80 |
| Analyst Decision | Hold | |
| Analyst Count | 29 | 0 |
| Target Price | ★ $25.85 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 24.1K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.33% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.99 | N/A |
| Revenue | ★ $2,198,237,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.36 | ★ N/A |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $14.68 | $16.77 |
| 52 Week High | $25.32 | $19.09 |
| Indicator | SRPT | JLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 32.11 |
| Support Level | $20.12 | $16.77 |
| Resistance Level | $23.70 | $18.69 |
| Average True Range (ATR) | 1.55 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 46.15 | 4.82 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.